Leerink Swann Calls Merck's (MRK) Odanacatib News a 'Positive Upside Surprise'

July 12, 2012 10:50 AM EDT
Get Alerts MRK Hot Sheet
Price: $61.17 -0.5%

Rating Summary:
    16 Buy, 6 Hold, 1 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 13 | Down: 22 | New: 54
Trade MRK Now!
Join SI Premium – FREE
Analysts at Leerink Swann this morning called Merck's (NYSE: MRK) early success of odanacatib a "positive upside surprise." Investors seem to be agreeing: Merck shares are up more than 4 percent at last check, marking a more than $5 billion gain in market value.

Leerink sees peak sales for odanacatib at $975 million in 2020, "depending on the final data, see global sales potential of $3B+ if MRK shows a relative reduction in hip fracture risk of 40%+."

The firm maintains an Outperform rating on Merck shares.

Visit our Analyst Ratings page on Merck to see all the market-moving analyst calls.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Add Your Comment